Capsida and AbbVie make $70M upfront deal for genetic medicines in eye diseases
AbbVie is expanding its partnership with gene therapy developer Capsida in a deal to develop genetic therapies for eye diseases.
The deal comes with a $70 million upfront payment, as much as $595 million in milestone payments, and possible commercial payments, according to a statement from the companies. Under the deal, they will identify and develop as many as three programs.
The deal is an expansion of AbbVie and Capsida’s 2021 partnership, in which AbbVie made a $90 million upfront payment and the companies agreed to work on central nervous system diseases. And in January, Capsida announced a partnership with Eli Lilly, taking in $55 million in upfront payments plus milestones to develop gene therapies for central nervous system diseases.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters